Literature DB >> 9063428

Reversal of protein-losing enteropathy with heparin therapy in three patients with univentricular hearts and Fontan palliation.

J P Donnelly1, A Rosenthal, V P Castle, R D Holmes.   

Abstract

We studied three pediatric patients with protein-losing enteropathy in conjunction with univentricular hearts and right atrial to pulmonary artery anastomosis (Fontan operation) before and during heparin therapy. Each patient showed dramatic improvements in symptoms, marked elevations in serum albumin levels, and quantitative reversal of enteric protein loss within a few weeks of beginning therapy. These findings suggest that heparin may be an important treatment for this poorly understood condition.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9063428     DOI: 10.1016/s0022-3476(97)70214-2

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  20 in total

1.  Protein-losing enteropathy after fontan operation: treatment with elementary diet in one case.

Authors:  G Guariso; A Cerutti; G S Moreolo; O Milanesi
Journal:  Pediatr Cardiol       Date:  2000 May-Jun       Impact factor: 1.655

2.  Hypoplastic Left Heart Syndrome.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-12

3.  Children with protein-losing enteropathy after the Fontan operation are at risk for abnormal bone mineral density.

Authors:  David J Goldberg; Kathyrn Dodds; Catharine M Avitabile; Andrew C Glatz; Jill L Brodsky; Edisio J Semeao; Elizabeth B Rand; Edna E Mancilla; Jack Rychik
Journal:  Pediatr Cardiol       Date:  2012-03-21       Impact factor: 1.655

4.  Clinical research priorities in adult congenital heart disease.

Authors:  Timothy Cotts; Paul Khairy; Alexander R Opotowsky; Anitha S John; Anne Marie Valente; Ali N Zaidi; Stephen C Cook; Jamil Aboulhosn; Jennifer Grando Ting; Michelle Gurvitz; Michael J Landzberg; Amy Verstappen; Joseph Kay; Michael Earing; Wayne Franklin; Brian Kogon; Craig S Broberg
Journal:  Int J Cardiol       Date:  2013-12-24       Impact factor: 4.164

5.  Canadian Cardiovascular Society 2009 Consensus Conference on the management of adults with congenital heart disease: complex congenital cardiac lesions.

Authors:  Candice K Silversides; Omid Salehian; Erwin Oechslin; Markus Schwerzmann; Isabelle Vonder Muhll; Paul Khairy; Eric Horlick; Mike Landzberg; Folkert Meijboom; Carole Warnes; Judith Therrien
Journal:  Can J Cardiol       Date:  2010-03       Impact factor: 5.223

6.  Fenestration of the Fontan circuit as treatment for plastic bronchitis.

Authors:  J Wilson; J Russell; W Williams; L Benson
Journal:  Pediatr Cardiol       Date:  2005 Sep-Oct       Impact factor: 1.655

7.  Oral budesonide treatment for protein-losing enteropathy in Fontan-palliated patients.

Authors:  Kurt R Schumacher; Michael Cools; Bryan H Goldstein; Viktoriya Ioffe-Dahan; Karen King; Diane Gaffney; Mark W Russell
Journal:  Pediatr Cardiol       Date:  2011-06-10       Impact factor: 1.655

Review 8.  Medical management of the failing Fontan.

Authors:  N S Ghanayem; S Berger; J S Tweddell
Journal:  Pediatr Cardiol       Date:  2007 Nov-Dec       Impact factor: 1.655

9.  The Fontan pathway: What's down the road?

Authors:  Sachin Khambadkone
Journal:  Ann Pediatr Cardiol       Date:  2008-07

10.  Heparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal epithelial barrier function.

Authors:  Lars Bode; Camilla Salvestrini; Pyong Woo Park; Jin-Ping Li; Jeffrey D Esko; Yu Yamaguchi; Simon Murch; Hudson H Freeze
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.